• ICER Issues More Measured Response With Final Evidence Report on Cost Effectiveness of Anabolic Agents for Osteoporosis

    July 20, 2017

    The Institute for Clinical and Economic Review (ICER) released this week its final evidence report assessing the comparative clinical effectiveness and cost of the osteoporosis drug therapies teriparatide and abaloparatide. The report includes a summary of a June 30, 2017 public meeting where ASBMR Professional Practice Committee Chair, Benjamin Leder, MD, testified to discuss concerns about the evidence being used for the report.

    The ASBMR shares ICER’s and the public’s concern with the high cost of anabolic osteoporosis therapies and enthusiastically support all efforts to make them more affordable to our patients. We were heartened to see that ICER metered its assessment as research shows that anabolic therapy can be of critical value for those most severely affected and for those who remain at high risk despite long-term treatment with other osteoporosis medications.

    "Evidence suggests that, for the right patients, both teriparatide and abaloparatide provide benefit over no treatment, but the limited availability of data from head-to-head trials makes it difficult to ascertain whether the agents are more effective than existing alternatives, such as bisphosphonates," noted David Rind, MD, MSc, Chief Medical Officer of ICER in a press release.

    Echoing the concerns raised by Dr. Leder in his testimony on behalf of the ASBMR, Dr. Rind went on to add that more research is needed "on the most clinically important outcomes, particularly hip fractures, along with further data on patient-centered outcomes, to understand the full impact of anabolic therapies."

    The ICER report serves as a “wake up call” to address the current crisis in the under treatment of osteoporosis. We recognize that anabolic therapy should not be the first choice intervention for most patients with osteoporosis, however, anabolic therapy can be of critical value for those most severely affected and for those who remain at high risk despite long-term treatment with other osteoporosis medications.


    To read the full report, please see ICER’s full report.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Policies and Procedures for more details